Episodes
-
In this episode of From Lab to Launch by Qualio we interview Joseph Mossel, CEO and co-founder of Ibex Medical Analytics. Joseph shares his journey from computer science to leading a transformative AI-driven company in pathology. Founded in 2016, Ibex aims to provide accurate, timely, and personalized cancer diagnoses using AI technology. Joseph discusses the challenges and insights from deploying AI in clinical settings, the importance of partnerships, and the company's vision for the next few years. Tune in to learn how Ibex's innovations are reshaping cancer diagnostics and making a significant impact on patient outcomes.
https://ibex-ai.com/https://www.linkedin.com/in/yossimossel/
00:00 Introduction to the Podcast
00:26 Meet Joseph Mossel, CEO of Ibex
01:14 The Founding and Vision of Ibex
05:59 Ibex's AI Technology and Its Impact
07:41 Challenges and Overcoming Them
09:54 AI in Cancer Diagnostics
15:12 Future of AI in Pathology
17:15 Partnerships and Collaborations
19:58 Advice for Labs and Entrepreneurs
23:29 Ensuring AI Reliability and Quality
25:48 Fun and Final ThoughtsQualio website:
https://www.qualio.com/Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcastApply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8Music by keldez
-
Earlier this year, Thermo Fisher Scientific opened its first clinical trial Innovation Lab in Center Valley, Pa., designed to foster a culture of collaboration by providing a dedicated space for industry partners to come together, share ideas and co-create solutions for the industry’s biggest challenges.
The global clinical trial market was valued at over $80 billion in 2023, and that’s projected to grow by 6.5% every year until 2030. But alleviating innovation silos is the only way to move the clinical trial industry forward and tackle its current challenges.
And it’s here that Senior Director of Innovation & Program Management Sarah Englert's mission is focused...
https://www.linkedin.com/in/sarah-blake-englert-70557421/
https://www.thermofisher.com/us/en/home.htmlQualio website:
https://www.qualio.com/Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcastApply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8Music by keldez
-
Episodes manquant?
-
Today we welcome Kerry Love, the co-founder of Massachusetts-based (and wonderfully named) Sunflower Therapeutics. Established in 2018, Sunflower is dedicated to advancing biologic medicines and enhancing global vaccine accessibility through cutting-edge protein manufacturing technologies.
As a women-owned organization, Sunflower has a stellar team of scientists and engineers renowned for their expertise in perfusion fermentation, purification process development, biopharmaceutical manufacturing, and quality management. Their mission-driven approach revolves around simplifying bioproduction complexities with their modular, automated, and fully integrated platform. This transformative technology empowers innovators to swiftly manufacture critical biologic products precisely where they're needed most.
https://www.linkedin.com/in/kerry-love-1a197811/https://sunflowertx.com/
Qualio website:
https://www.qualio.com/Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcastApply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8Music by keldez
-
Carna Health is focused on applying technology to revolutionize kidney care by unlocking the early detection and management of chronic kidney disease (CKD). They provide clinical-grade software as medical devices that deliver instant health metrics, such as creatinine, eGFR, and uACR levels, from small patient samples. Their platform integrates with existing healthcare systems and electronic healthcare records, promoting proactive and patient-centric care underpinned by accurate, real-time patient data.
CEO and co-founder Salvatore Viscomi, MD, joined Meg to talk about the Carna Health mission, where current kidney care is going wrong, and what the future holds for kidney patients.
More about Dr. Viscomi:
Dr. Viscomi is the CEO and co-founder of Carna Health, a Boston-based SaMD company focused on revolutionizing how chronic kidney disease is spotted and treated early.
https://carna.health/https://www.linkedin.com/in/salvatore-viscomi/
Qualio website:
https://www.qualio.com/Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcastApply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8Music by keldez
-
Dr. Jonathan Hill, VP of Science and Technology and co-founder of Wasatch Biolabs joins the podcast today to talk about the future of genetic testing technology.
Dr. Hill shares his journey in genetics, starting from his undergraduate days to co-founding multiple biotech companies. They discuss the cutting-edge genomic and bioinformatic methods being developed at Wasatch Biolabs, including targeted DNA methylation sequencing and its significant implications for personalized medicine and early disease detection. Dr. Hill also elaborates on the integration of lab work and data analysis in genetic research, partnerships in diagnostic advancements, the role of AI in the future of genetic testing, and the importance of quality management in product development. Additionally, he speaks about the challenges faced in implementing these technologies and how they are being addressed. The conversation concludes with Dr. Hill's vision for the future of genetic testing and his approach to preparing students for the industry’s evolving landscape.
00:00 Introduction to the Episode
00:25 Meet Dr. Jonathan Hill
01:45 Dr. Hill's Journey in Genetics
03:27 Understanding DNA Methylation Sequencing
06:15 Applications in Personalized Medicine
15:06 Challenges in Implementing Assays
18:40 Future of Genetic Testing Technology
23:14 Importance of Collaborations and Partnerships
26:58 Fun and Personal Insights
27:43 Conclusion and Contact Information
More about Dr. Hill:
Dr. Hill is the VP of Science and Technology and a co-founder of Wasatch BioLabs, a biotechnology company committed to transforming the field of diagnostics. The company delivers reliable laboratory services, offering transparent testing and accurate results for biotech firms, patients, and research institutions.
https://www.wasatchbiolabs.com/https://www.linkedin.com/in/jonathon-t-hill/
Qualio website:
https://www.qualio.com/Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcastApply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8Music by keldez
-
Join us with guest Dr. Rolland Carlson, CEO of Immunexpress to talk about the transformative work happening in sepsis diagnosis.
Dr. Carlson discusses the importance of rapid sepsis diagnosis. The episode covers challenges faced during product development, regulatory achievements, and future plans for sepsis diagnostics. Dr. Carlson also shares advice on ensuring product quality and navigating FDA clearances.
00:00 Introduction to From Lab to Launch
00:25 Meet Dr. Rolland Carlson, CEO of Immunexpress
01:31 Challenges and Innovations in Sepsis Diagnosis
03:01 Impact of COVID-19 on Clinical Trials
04:17 The Vision Behind Septicite Rapid
05:17 Technical Insights into Sepsis Diagnosis
14:00 Regulatory Achievements and Quality Management
16:58 Integrating Septicite Rapid in Clinical Workflows
24:00 Future Innovations in Sepsis Diagnostics
25:34 A Personal Note from Dr. Carlson
26:29 Conclusion and Farewell
https://immunexpress.com/https://www.linkedin.com/in/rollie-carlson-ph-d-059074a/
Qualio website:
https://www.qualio.com/Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcastApply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8Music by keldez
-
In this episode we bring David Suhy, co-founder and Chief Scientific Officer at Earli back to the podcast. David shares the heartfelt founding story of Earli, the company's mission to make cancer a benign experience by catching it early, and their unique approach utilizing synthetic promoters for early cancer detection and treatment.
He discusses challenges faced in clinical trials, the importance of quality and safety in research, and provides advice for other startups in life sciences. David also talks about the recent advancements at Earli, their funding journey, and offers valuable insights on navigating the dynamic field of scientific innovation.
The episode concludes with a light-hearted discussion about David's passion for making pizzas in his backyard wood-fired oven.
00:00 Introduction and Podcast Overview
00:37 Guest Introduction: David Suhy from Earli
01:19 The Founding Story of Earli
04:24 Earli's Unique Approach to Cancer Detection
06:33 Challenges and Innovations in Cancer Treatment
10:06 Clinical Trials and Lessons Learned
15:30 Funding and Financial Strategies
18:56 Future Plans and Developments
21:14 Quality and Safety in Research
23:43 Advice for Entrepreneurs and Scientists
25:27 Fun Facts and Closing Remarks
https://www.earli.comhttps://www.linkedin.com/in/davidsuhy/
Qualio website:
https://www.qualio.com/Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcastApply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8Music by keldez
-
This episode we're joined by Dr. Joshua Lee, a clinician, researcher, and professor specializing in medication-assisted treatment (MAT) for alcohol and opioid use disorders. Dr. Lee discusses his extensive research on medications such as naltrexone and buprenorphine, their significance in treating substance use disorders, and the transformative potential of telemedicine platforms like Oar Health. He highlights the underutilization of effective medications in primary care, the barriers to accessibility, and the enduring stigma associated with addiction. The conversation also touches on emerging trends and the future of addiction treatment.
Dr. Lee's Bio
Joshua specializes in medication-assisted treatment of alcohol and opioid use disorders. He conducts clinical trials and treats patients struggling with addiction as a primary care physician. As a Professor at NYU Grossman School of Medicine, he leads the Addiction Medicine Fellowship and conducts research focused on justice and community outcomes.
https://www.oarhealth.com/
https://med.nyu.edu/faculty/joshua-d-lee
https://x.com/drjoshuadlee
00:00 Introduction and Podcast Overview
00:38 Introducing Dr. Joshua Lee
01:20 Clinical Trials and Medication Insights
03:46 Challenges in Alcohol and Opioid Treatment
08:50 Telemedicine and Its Impact
11:59 Addressing Misconceptions and Barriers
19:35 Success Rates and Future Trends
30:14 Fun Personal QuestionQualio website:
https://www.qualio.com/Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcastApply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8Music by keldez
-
In this episode we're joined by Justin Zenanko, CEO and co-founder of SynerFuse to discuss groundbreaking technique combining spinal fusion and direct nerve stimulation to treat chronic low back pain, aiming to eliminate the need for postoperative opioids. Justin delves into the inspiration behind the technology, its clinical results, and the company's approach to quality and regulatory management. He also provides insights on raising funds in a competitive market and the potential future applications of SynerFuse's technology.
Justin's Bio
Justin Zenanko, CPA, MDiv, is the president, CEO, and co-founder of SynerFuse, Inc., a Minnesota-based company innovating the spine industry with its integrated approach which combines spinal fusion and direct nerve stimulation to address the chronic low back pain that is unaddressed in about 40% of the 500,000 traditional spinal fusion surgeries that take place annually in the US alone. The SynerFuse approach aims to eliminate the post-surgical need for addictive opioids.
Link to SynerFuse website: https://www.synerfuse.com/
00:00 Introduction and Welcome
00:41 Meet Justin Zinenko: From CPA to MedTech Innovator
03:16 The Birth of SynerFuse: Combining Spinal Fusion with Nerve Stimulation
05:29 Clinical Results and Patient Success Stories
08:46 Quality and Regulatory Approaches in MedTech
10:29 Future Applications and Innovations
14:59 Advice for Aspiring Entrepreneurs
17:51 Fun Insights and Closing RemarksQualio website:
https://www.qualio.com/Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcastApply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8Music by keldez
-
**UPDATE** Since this episode was recorded, Takeda announced the results of the phase 3 soticlestat trials, which did not meet their primary endpoints.
We welcome Dr. Toshiya Nishi and Jason Tardio from Ovid Therapeutics. Dr. Nishi, with over 20 years of experience in drug discovery, discusses his role in the development of soticlestat and ongoing research on KCC2 activators for neurological disorders. Jason Tardio, Ovid's COO, shares insights on the company's focus on rare neurological disorders, including epilepsy, and its strategic initiatives for advancing treatments. Listen to their inspiring journey from the inception of Ovid Therapeutics to its current breakthroughs, and their perspectives on fostering a quality-driven and risk-tolerant culture in drug development.
https://ovidrx.com/
00:00 Introduction and Welcome
00:40 Meet the Guests: Dr. Toshiya Nishi and Jason Tardia
02:04 The Journey of Ovid Therapeutics
03:58 Discovering Saticklistat: A Serendipitous Breakthrough
08:35 Strategic Initiatives and Future Directions
13:48 Collaboration and Culture at Ovid Therapeutics
17:38 Ensuring Quality in Drug Development
21:50 Personal Insights and Closing Remarks
24:07 Conclusion and FarewellQualio website:
https://www.qualio.com/Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcastApply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8Music by keldez
-
Join us as we discuss viral diagnostics and pharmacology with Dr. Nigel McCracken, Chief Operating Officer of Virax Biolabs. Dr. McCracken shares his expertise in drug development, focusing on oncology and infectious diseases, and discusses the company's pioneering work in detecting immune responses and diagnosing viral diseases. The conversation covers the impact of technology advancements in the past decade, the introduction of the Immune Select Profile in the Virax Immune T Cell Diagnostic Platform, and the evolving landscape of viral diagnostics post-COVID-19. Dr. McCracken also shares insights on maintaining high-quality standards in R&D and offers advice for aspiring professionals in the fields of drug development and diagnostics.
https://www.viraxbiolabs.com/
00:00 Introduction and Welcome
00:40 Meet Dr. Nigel McCracken
01:29 Nigel's Journey in Pharmacology
05:08 Innovations at Virax Biolabs
09:05 Impact of COVID-19 on Viral Diagnostics
12:53 Ensuring Quality in Diagnostics
16:37 Future Trends in Viral Diagnostics
20:20 Advice for Aspiring Researchers
23:13 Nigel's Personal Insights
24:20 Conclusion and FarewellQualio website:
https://www.qualio.com/Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcastApply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8Music by keldez
-
Join us in this inspiring episode of From Lab to Launch as we sit down with Marna Pacheco, the innovative founder of CapeAble Weighted Products. Marna turned a personal challenge into a pioneering enterprise that integrates fashion with function, providing therapeutic weighted products to those in need, from individuals with autism to medical patients across various settings.
Marna shares her journey from designing a unique weighted cape for her daughter to founding CapeAble.Insight into the smartweight technology that sets CapeAble products apart in efficacy and style.Discussion on how CapeAble's products are making a significant impact in the medical field through non-pharmaceutical interventions.CapeAble's expansion into medical applications.
You'll learn:https://www.capeable.com/
Qualio website:
https://www.qualio.com/Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcastApply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8Music by keldez
-
This episode of the From Lab to Launch podcast, brought to you by Qualio, features Dr. Sam Clark, CEO of Terran Biosciences. With a background in neurosciences from MIT and an MD and PhD from Columbia University, Dr. Clark shares his journey from academia to leading a pioneering company in neuropsychiatric therapeutics. He discusses the challenges and innovations in the development and supply of GMP psychedelic compounds, highlighting how these substances are making significant strides toward transforming mental health treatment.
Dr. Clark also explores Terran Biosciences' approach to overcoming drug development hurdles, emphasizing quality management and patent strategies to ensure the delivery of affordable, effective treatments. His insights offer a glimpse into the future of psychedelics in mainstream medicine and the broader implications for treating various disorders beyond mental health.
https://terranbiosciences.com/Dr. Sam Clark's LinkedIn: https://www.linkedin.com/in/sam-clark-md-phd-133139199/
00:00 Welcome to From Lab to Launch!
00:40 Introducing Dr. Sam Clark and Terran Biosciences
01:23 Dr. Clark's Journey: From Academia to Neuropsychiatric Therapeutics
02:48 The Renaissance of Psychedelic Therapeutics
04:36 Challenges and Innovations in Drug Development
08:36 Quality Management at Terran Biosciences
10:23 The Future of Psychedelics in Mainstream Medicine
12:46 Expanding Beyond Neuropsychiatry: Terran's Broader Impact
14:02 Navigating Innovation and Ethics in Patenting
17:48 Advice for Aspiring Scientists and Innovators
20:42 Dr. Clark's Personal Inspirations and Closing Thoughts
22:21 How to Follow Dr. Clark and Terran Biosciences
23:00 Wrapping Up and How to Engage with From Lab to LaunchQualio website:
https://www.qualio.com/Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcastApply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8Music by keldez
-
Listen in on our conversation with Rob Etherington, CEO of Clene Nanomedicine, a company pioneering nanotherapeutics for neurodegenerative diseases like ALS, multiple sclerosis, and Parkinson's.
Rob discusses Clene's unique approach to improve mitochondrial function through a novel nanotherapeutic called CNM-au8, which has shown promising outcomes in clinical trials. He highlights the challenges in drug development, including funding and FDA approval processes, and underscores the importance of resilience, continuous learning, and strategic partnerships in advancing biotech innovations. The episode also touches on Rob's personal philosophy on leadership and the importance of women in leadership roles.
https://clene.com/
https://www.linkedin.com/in/rob-etherington-431718/Qualio website:
https://www.qualio.com/Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcastApply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8Music by keldez
-
Today we interview with Dan Lunz, co-founder and CEO of Previse, an innovative medical solutions company specializing in cancer prevention and early detection. Lunz talks about his journey from being a Marine to leading a pioneering medical company. He discusses the scientific technology behind Previse, which started out as research for predicting esophageal cancer in patients with Barrett's esophagus. Lunz also shares about the company's current fundraising activities, commercialization plans, compliance with regulatory standards, and long-term goals for cancer detection. He hints at exciting future announcements about Previse's new developments, tests, and pipeline technologies.
https://previsedx.com/https://www.linkedin.com/in/danlunz/
00:43 The Journey of Previse: Aiming for Early Cancer Detection
05:24 The Previse Technology: A New Approach to Cancer Detection
07:45 The Impact of Previse in the Medical Field
10:13 Fundraising and the Future of Previse
14:51 Navigating the Regulatory Landscape
18:02 Balancing Innovation and Compliance
21:15 Long-term Goals and Future DevelopmentsQualio website:
https://www.qualio.com/Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcastApply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8Music by keldez
-
In this episode we welcome Pam Hurley, the founder and president of Hurley Write Inc., who specializes in professional writing and communication training. Pam discusses how proper writing can lead to more effective professional communication in life sciences, and how precision and confidence in writing can help professionals achieve their goals.
She highlights the importance of clear and concise communication, especially in regulatory submissions, research publications, or internal communications. Delving into the common writing challenges, Pam mentions the lack of understanding of the outcome and disregarding reader's readability and understanding as some. She concludes by highlighting the crucial role of effective writing in business and organizational decision-making and shares tips for enhancing writing skills.
LinkedIn.com/in/Hurleywritehttps://www.hurleywrite.com/
00:40 Meet the Guest: Pam Hurley
02:14 Pam's Journey into Professional Writing
04:06 The Impact of Effective Writing in Life Sciences
08:15 Common Writing Challenges in Professional Settings
16:16 The Role of Writing in Decision Making
17:50 The Future of Writing: AI and Beyond
19:12 Pam's Favorite Writers and Reading Habits
21:42 Closing Remarks and Contact InformationQualio website:
https://www.qualio.com/Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcastApply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8Music by keldez
-
In this episode we interview Mark McDonough, the CEO of ChromaCode. The episode explores McDonough's journey to ChromaCode, from his early career as a naval officer to his roles at various medical and diagnostic companies. Under McDonough's leadership, ChromaCode has excelled in creating a high-definition PCR platform which enables fast, accurate, and affordable cancer diagnosis. The platform is particularly beneficial as it requires less patient tissue, provides rapid results, and has a lower cost than traditional diagnostic methods. McDonough also discusses the importance of partnerships in their go-to-market strategy and shared his insights on hiring and team development in today's competitive market. Looking ahead, ChromaCode expects to become a leader in developing innovative products for disease diagnosis, with a focus on patient-centered outcomes.
https://www.chromacode.com/https://www.linkedin.com/in/mark-mcdonough-b1055216/
00:00 Introduction to the Podcast
00:40 Meet the Guest: Mark McDonough, CEO of ChromaCode
01:47 Mark's Journey to ChromaCode
06:05 Insights on Leadership and Building High Performing Teams
08:10 ChromaCode's Innovative Approach to PCR Testing
10:36 ChromaCode's Contribution to Precision Medicine
13:50 The Importance of Partnerships in ChromaCode's Strategy
16:33 Future Prospects for ChromaCode
18:27 Getting to Know Mark: Personal Interests
19:13 Closing Remarks and Contact Information
About Mark McDonough
Mark has over 25 years of experience helping build high growth HealthCare organizations. He is passionate about his team, his customers, and the patients that he and they are privileged to help serve. He most recently was the CEO of Pierian (now Velsera) which he led to a successful sale to Summa Equity, a private equity firm, in 2022. Prior to Pierian, he led CombiMatrix for five years, culminating in a sale to Invitae in 2017. Over his career, Mark has held various executive and commercial positions, and served as a US Naval Officer.Qualio website:
https://www.qualio.com/Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcastApply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8Music by keldez
-
Join us as we dive into the world of groundbreaking scientific discovery with Chris Burres, a renowned Chief Scientist. In this episode, Chris unveils the mysteries of a unique, soccer ball-shaped molecule that could be the key to unlocking secrets of health and longevity.
Discover how this extraordinary molecule, small enough to hold any atom from the periodic chart, might revolutionize our understanding of wellness and aging. Chris shares insights into the foundational principles that drive this innovative research and the potential life-changing benefits it holds.
Furthermore, hear firsthand the compelling success stories and testimonials from users of "MyVitalC." These narratives not only shed light on the practical implications of Chris's work but also illustrate the profound impact this discovery could have on our daily lives.
Whether you're a science enthusiast, a health and wellness aficionado, or simply curious about the latest in scientific breakthroughs, this episode promises to offer a fascinating blend of scientific exploration and real-world applications. Tune in to get a glimpse into the future of health science with Chris Burres guiding the way.
https://www.myvitalc.com/
More about Chris Burres
Chris Burres is the Co-Founder of MyVital-C as well as the co-owner of SES Research Inc. and he runs a podcast about SEO marketing which is really popular. Chris is also a health expert specializing in ESS60, a Nobel Prize-winning molecule with exceptional antioxidant properties. He’s been on numerous health and wellness podcasts sharing how ESS60 can revolutionize health and wellness.
https://www.linkedin.com/in/chrisburresQualio website:
https://www.qualio.com/Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcastApply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8Music by keldez
-
In this episode of "From Lab to Launch" by Qualio, Meg welcomes Ravi Samavedam, the Chief Innovation Officer of Azzur Group. With over two decades of experience as a seasoned biochemical engineer, Ravi is a driving force behind Azzur's groundbreaking approach to lab spaces and cleanrooms.
Discussion Highlights:
Ravi delves into Azzur Group's evolution since its formation in 2010, emphasizing its roots in equipment and facilities for the biopharma industry. The conversation unfolds with a focus on Azzur's revolutionary "Cleanrooms on Demand" concept, drawing parallels to Legos for its flexibility and efficiency. Ravi explains the benefits of licensing lab space, offering a hybrid model that accelerates time-to-market for biotech and pharma companies.The conversation explores how Azzur ensures GMP compliance in multiproduct facilities, emphasizing quality systems and strict agreements. Ravi elaborates on Azzur's one-stop-shop approach, providing a range of services under one roof, from testing labs to consulting. The discussion touches on the lab space shortage, both pre- and post-COVID, and the potential implications for the industry.
Ravi shares insights into emerging trends, expressing particular excitement for the potential decentralization of cell therapy manufacturing near hospitals. The episode concludes on a lighter note as Ravi reveals his personal interest in geography.
Connect and Learn More:
For those intrigued by Azzur Group's innovative solutions, virtual facility tours and more content can be found on their YouTube channel. Additionally, the Azzur website offers a wealth of information, including recent articles and client testimonials. Listeners are encouraged to explore further at Azzur Group's Website and YouTube Channel.This episode provides a comprehensive understanding of Azzur Group's transformative contributions to the biotech and pharma sectors, offering a glimpse into the future of flexible and efficient lab spaces.
Qualio website:
https://www.qualio.com/Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcastApply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8Music by keldez
-
In this episode, Meg is joined by Troy Bannister, the co-founder and chief strategy officer at Particle Health. Particle Health is a company revolutionizing the accessibility, sharing, and utilization of healthcare data to simplify navigation for patients and healthcare providers. Troy shares his inspiration behind starting Particle Health and dives into the challenges and strategies the company employed to navigate regulatory compliance and foster successful partnerships in the highly regulated healthcare industry.
The conversation delves into the importance of caring passionately about the mission, overcoming setbacks, and the role of partnerships in achieving Particle Health's mission. Troy provides insights into the evolving landscape of healthcare data sharing, emphasizing the potential for emerging trends and technologies to democratize healthcare data, leading to increased innovation and benefits for individuals.
This episode provides valuable insights into the challenges, strategies, and future trends in healthcare data access and innovation, making it a must-listen for those interested in the intersection of technology and healthcare. Connect with Troy on LinkedIn for further discussions and updates.
https://www.particlehealth.com/https://www.linkedin.com/in/troy-bannister-259a3235/
Qualio website:
https://www.qualio.com/Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcastApply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8Music by keldez
- Montre plus
